Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

John Sarantopoulos

Citation

Annals of Oncology (2019) 30 (suppl_5): v159-v193. 10.1093/annonc/mdz244

Authors

J. Sarantopoulos1, G. Fotopoulos2, F.Y. Tsai3, M.S. Beg4, A.A. Adjei5, Y. Lou6, M. Seetharam7, M.A. Villalona-Calero8, J. Melear9, M. Janat-Amsbury10, H. Beever11, L. Mouritsen12, M. Wade12, B.V. Bryan12, D.J. Bearss13

Author affiliations

  • 1 Hematology/oncology, Institute for Drug Development Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, 78229-3264 - San Antonio/US
  • 2 Hematology/oncology, Institute for Drug Development Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, 78229-3264 - San Antonio/US
  • 3 Hematology/oncology, HonorHealth Research Institute, 85258 - Scottsdale/US
  • 4 Hematology/oncology, University of Texas Southwestern Medical Center at Dallas, 75390-8576 - Dallas/US
  • 5 Oncology, Mayo Clinic, 55905 - Rochester/US
  • 6 Hematology/oncology, Mayo Clinic, 32224 - Jacksonville/US
  • 7 Medical Oncology, Mayo Clinic in Arizona, 85016 - Phoenix/US
  • 8 Oncology, Miami Cancer Institute Baptist Health, 33176 - Miami/US
  • 9 Hematology/oncology, Texas Oncology Austin-Midtown, 78705 - Austin/US
  • 10 Medical, Tolero Pharmaceuticals, Inc., 84043 - Lehi/US
  • 11 Clinical Operations, Tolero Pharmaceuticals, Inc., 84043 - Lehi/US
  • 12 Biomarker Development, Tolero Pharmaceuticals, Inc., 84043 - Lehi/US
  • 13 Office Of The Ceo, Tolero Pharmaceuticals, Inc., 84043 - Lehi/US
More

Resources

Abstract 2555

Background

TP-0903 is a novel, oral small molecule AXL kinase inhibitor impacting oncogenesis and resistance. AXL is upregulated in many solid tumors and influences the mesenchymal phenotype, which drives resistance to targeted cancer therapeutics, traditional chemotherapies, and immuno-oncology agents.

Methods

A dose escalation study was performed to examine the safety and clinical activity of TP-0903 in patients with advanced solid tumors. Patients received oral TP-0903 once daily for 21 of 28-day cycles. Nine dose levels were explored using modified 3 + 3 dose escalation rules. The primary objective of the trial was to identify the maximum tolerated dose of TP-0903 prior to expanding into refractory colorectal, platinum refractory/resistant ovarian cancer and TP-0903 in combination with immunotherapy or EGFR tyrosine kinase inhibitor in immunotherapy-resistant tumors or non-small cell lung cancers. Potential biomarkers were evaluated using liquid biopsies and pre-and post-dose tumor biopsies will be reported.

Results

Thirty-six patients were enrolled between December 2016 and April 2019 receiving 1.5 to 37mg/m2 over 9 cohorts. The most frequently observed >Gr3 AEs were thrombocytopenia (3), anemia (2), nausea (2), syncope (2), and vomiting (2), all manageable with supportive care. Grade 4 thrombocytopenia was the dose limiting toxicity observed in one patient in cohort 8 (28 mg/m2), reoccurring as grade 3 thrombocytopenia in 2 patients in cohort 9 (37mg/m2) without meeting DLT criteria. Patients are currently still ongoing in cohort 9. Eleven patients, (11/36, 30.6%), had stable disease with a median duration of 3.7 months (range 1.6 to 7.4+ months). Baseline serum soluble AXL of all enrolled patients was determined by immunoassay and indicated higher levels in patients with documented stable disease vs. progressive disease (p = 0.0332).

Conclusions

The oral small molecule AXL kinase inhibitor TP-0903 is well tolerated with a manageable safety profile. Hematologic toxicity was observed as a DLT. Future studies will evaluate the role of TP0903 in selected disease cohorts as monotherapy and in combination. Serum soluble AXL will be evaluated as a potential predictive biomarker of response.

Clinical trial identification

NCT: 02729298.

Editorial acknowledgement

Legal entity responsible for the study

Tolero Pharmaceuticals, Inc.

Funding

Tolero Pharmaceuticals, Inc.

Disclosure

J. Sarantopoulos: Research grant / Funding (institution): Tolero. G. Fotopoulos: Research grant / Funding (institution): Tolero Pharmaceuticals. F.Y. Tsai: Advisory / Consultancy: Tempus Lab; Officer / Board of Directors, Co-Founder: Caremission LLC; Shareholder / Stockholder / Stock options: Salarius Pharmaceuticals. M.S. Beg: Research grant / Funding (institution): Tolero Pharmaceuticals. A.A. Adjei: Research grant / Funding (institution): Tolero Pharmaceuticals. Y. Lou: Research grant / Funding (institution): Tolero Pharmaceuticals; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Stem Centrx; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Vaccinex; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): MacroGenics. M. Seetharam: Research grant / Funding (institution): Tolero Pharmaceuticals. M.A. Villalona-Calero: Research grant / Funding (institution): Tolero Pharmaceuticals; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Bristol Meyers; Research grant / Funding (institution): Novocure; Research grant / Funding (institution): Guardant. J. Melear: Research grant / Funding (institution): Tolero Pharmaceuticals. M. Janat-Amsbury: Full / Part-time employment: Tolero Pharmaceuticals. H. Beever: Full / Part-time employment: Tolero Pharmaceuticals. L. Mouritsen: Full / Part-time employment: Tolero Pharmaceuticals. M. Wade: Full / Part-time employment: Tolero Pharmaceuticals. B.V. Bryan: Full / Part-time employment: Tolero Pharmaceuticals. D.J. Bearss: Leadership role, Full / Part-time employment: Tolero Pharmaceuticals.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings